Earnings Had Better Start to Matter<br />By Rev Shark<br />RealMoney.com Contributor<br />4/20/2010 8:34 AM EDT <br /><br />To be tested is good. The challenged life may be the best therapist. <br />-- Gail Sheehy<br /><br />We are looking at a positive open as market players shift their focus away from the Goldman Sachs (GS) fraud charges, but there isn't much reaction to earnings reports so far. IBM (IBM) is trading down following its report, Goldman is up a few cents on blowout numbers, Coke (KO) and Johnson & Johnson (JNJ) are down and Brinker (EAT) and Northern Trust (NTRS) came in below expectations. <br /><br />Despite the mediocre response to earnings, we are spiking up as oil and commodities are bouncing and financials are a bit less worried that they will suffer the same fate as Goldman. Part of the strength may also be due to optimism about the Apple (AAPL) report due out after the close this afternoon. <br /><br />Apple is probably the most important stock in the market, and it is going to go a long way in determining market direction. Everyone knows that the company tends to lowball its guidance, so the market will not be a surprised when Apple beats estimates. The question will be whether it beats them by enough to keep this market chugging. AAPL is up more than 20% since this rally started back in early February, so plenty of good news has already be priced in. <br /><br />The reaction to AAPL is going to set the tone in the near term, and with expectations sky-high, there is a fair amount of risk. <br /><br />I'm a bit puzzled by the strength this morning. None of the major earnings reports are seeing strong reactions, so it seems to be mostly the weaker dollar that is boosting oil, gold and commodities -- that action is responsible for the strength. We really need earnings to be the main driving force if this market is going to continue its steady move higher. <br /><br />The thing that troubles me most about this market is that the action under the surface was much weaker yesterday than reflected in the Dow Jones Industrial Average and S&P 500. Breadth was soundly negative and most of the small-caps I followed did not bounce back much at all when the indices strengthened late in the day on Monday. <br /><br />China stocks, which are one of my key measures of speculative momentum, have been acting very poorly for about a week now and continue to see pressure as China makes moves to cool off its real estate market. When we start losing the hot-money sectors like China, and when small-caps underperform as they did yesterday, I grow much more concerned about the potential for sustained momentum. <br /><br />Despite the selling of the last two days, the indices still have barely corrected at all, but the Goldman news did result in a few cracks in our uptrend. The issue now is whether the dip-buyers can continue their aggressive buying of any minor pullback. They certainly are looking frisky in the early going today, but the real test will not come until AAPL earnings are issued this evening. <br /><br />I'm looking for this hot open to cool off fairly quickly and expect choppy action as we wait for tonight's earnings. The tepid response to key earnings looks like a worrisome sign, but so far the market seems focused on other issues. If we don't see better reaction to earnings pretty quickly, I'll be much more concerned about the health of our uptrend. <br />-----------------------------<br />Briefing.com<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: ATHR +5.7% (also tgt raised to $46 at Brigantine, target raised to $48 from $42 at Jefferies following above consensus Q1 results and Q2 guidance ), UNH +3.7%, ESLR +3.4%, STLD +3.0%, AVGO +2.6%, ZION +1.8%, NVS +1.0% (Novartis to reorganize U.S. staff; reports 1Q10 results - WSJ), COH +0.9%. <br /><br />M&A news: CKR +6.3% CKE Restaurants declares takeover proposal superior; gives notice that it is prepared to terminate the merger agreement with affiliates of Thomas H. Lee Partners, LP. <br /><br />Select European financial related names showing strength: DB +2.6%, AIB +2.6%, IRE +2.6%, ING +1.7%. <br /><br />Select metals/mining stocks trading higher: MT +2.2%, BHP +1.8%, BBL +1.2%, RTP +0.4%. <br /><br />Other news: ARRY +39.1% (has entered into an agreement with Novartis for the worldwide development of the small-molecule MEK inhibitors ARRY-162 and ARRY-300 and other MEK inhibators), JSDA +27.1% (Target Stores offer Jones Soda Co.'s New GABA infused beverage nationwide), ABK +10.3% (still checking), UNIS +6.9% (Cramer makes positive comments on MadMoney), XOMA +5.6% (XOMA 052 shows potent in vitro inhibition of interleukin-6 production in human myeloma cells), THC +3.6% (still checking), RIG +3.1% (will begin trading on SIX Swiss Exchange), ATPG +3.0% (received approval for the commingling of two zones at the Atwater Valley 63 #4 well), SSN +2.4% (advises that it expects to be drilling the Gary #1-24H well in mid to late May 2010), WYNN +2.2% (Cramer makes positive comments on MadMoney), FRO +1.8% (still checking). <br /><br />Analyst comments: MWW +4.1% (upgraded to Outperform at Credit Suisse; tgt raised to $22 ), MGM +3.3% (added to Conviction Buy List at Goldman; Cramer makes positive comments on MadMoney), HK +2.7% (upgraded to Outperform from Market Perform at FBR Capital), IPI +1.9% (upgraded to Hold from Sell at Soleil; maintains $25 tgt), TOT +1.6% (upgraded to Buy from Hold at Citigroup), POT +0.8% (upgraded to Hold from Sell at Soleil).<br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: MTG -12.1% (also filed for a mixed shelf offering for an indeterminate amount), FALC -7.4%, EAT -5.6%, SVU -4.9%, NTRS -4.5%, WERN -2.2%, FRX -1.8%, IBM -1.8%, KO -1.4%, USB -1.1%, LNCR -0.4% (light volume). <br /><br />Select mortgage insurer related names pulling back following MTG results: RDN -3.5%, PMI -3.4%, MBI -1.1%.<br /><br />Other news: NIV -7.7% (prices ~7.3 mln shares at $3.29), HGSI -5.5% (Human Genome and GlaxoSmithKline announce topline 76-week results of Phase 3 trial of Benlysta in Systemic Lupus Erythematosus), CIGX -4.3% (files for 18,050,847 Share Common Stock offering selling stockholders), GILD -1.2% (terminates Ph. II clinical trial of GS 9450 in patients with chronic hepatitis C). <br /><br />Analyst comments: GCA -1.7% (downgraded to Hold from Buy at Lazard), CSTR -1.6% (downgraded to Market Weight from Overweight at Thomas Weisel).